Smiling elderly woman in a blue sweater reaching out to children at an outdoor family gathering with colorful decorations.

Comprehensive Adult Hemostasis & Thrombosis Center

Why Choose Montefiore Einstein for Bleeding & Clotting Disorders Care?

The Montefiore Einstein Comprehensive Adult Hemostasis & Thrombosis Center is a national leader, providing comprehensive state-of-the-art care for adults and children with the full range of bleeding and clotting disorders, such as hemophilia, von Willebrand disease, platelet disorders, vascular disorders associated with bleeding tendencies, and rare factor deficiencies. Designated as a Comprehensive Hemophilia Treatment Center by the Health Resources and Services Administration since 2016, our federally funded Center is the first to be approved in the New England region for more than 40 years. Our world-renowned hematologists, orthopedic surgeons, obstetricians and gynecologists, cardiologists, dentists, physical therapists and other specialists provide seamless coordinated care at locations in the Bronx and the broader New York metropolitan area, including Westchester County and the Hudson Valley.

We use a personalized care approach tailored to addressing each patient’s unique needs. We offer a complete spectrum of services from prevention, diagnosis and treatment to social and support services, genetic counseling and education. Our team of experts uses the most advanced diagnostics and latest treatments—from bispecific antibody and plasma and recombinant clotting-factor therapies—to expand the possibilities of treatment for the full range of bleeding and clotting disorders; prevent, reduce or eliminate painful and potentially life-threatening bleeding or clotting complications; optimize health; and enhance quality of life.

Home to more than 1,000 patients with bleeding and congenital thrombotic disorders, we are an international referral site for the most complex cases. Our innovative multidisciplinary Center is one of the premier destinations for clotting disorders and works closely with our Thrombosis Prevention and Treatment Program, one of the largest programs of its kind in the nation. Our Center also collaborates closely with the Women’s Blood Disorders Program and the Children’s Hospital at Montefiore Einstein Adolescent Menstrual Program (CHAMP) where patients are jointly evaluated by both adolescent gynecology and pediatric hematology specialists. We are committed to providing the highest-quality patient- and family-centered care for all patients and ensuring each child and adolescent has a smooth transition from pediatric to adult care. Through our clinical trials, our patients can also access emerging technologies and innovative treatments that are otherwise unavailable to the general public.

Your Comprehensive Adult Hemostasis & Thrombosis Center Team

Our multidisciplinary team of internationally recognized experts specializes in the prevention, diagnosis and treatment of the full range of bleeding and clotting disorders in adults and children, delivering comprehensive, personalized care focused on optimizing health and improving the quality of life for each patient.

Henny H. Billett, MD

Director, Comprehensive Adult Hemostasis & Thrombosis Center
Bitalina Arroyo, LMSW

Bitalina Arroyo, LMSW

Social Worker
Beatriz Casiano

Beatriz Casiano

Research Associate

Advanced Diagnostics & Treatments for Bleeding & Clotting Disorders

We use the latest diagnostics and treatments for the prevention, diagnosis and management of the full range of bleeding and inherited clotting disorders in adults and children. Our team offers comprehensive, personalized care focused on optimizing health and quality of life.

Bleeding Disorders

For bleeding disorders, we use the most advanced laboratory testing, such as coagulation studies, platelet analysis, clotting-factor assays, genetic testing with massively parallel sequencing and inhibitor testing, as well as tests for other associated medical conditions. For prenatal diagnosis, we also offer advanced noninvasive prenatal screening tests and work together with specialists from our Department of Obstetrics & Gynecology and Women's Health who specialize in performing chorionic villus sampling, amniocentesis and cordocentesis for the collection of circulating fetal cells, as well as sophisticated blastocyst biopsy for preimplantation embryo diagnostics.

Depending on the diagnosis, we offer personalized and targeted treatments. For patients with hemophilia and other bleeding disorders, we offer a wide range of treatments to reduce the incidence of joint, muscle and soft-tissue bleeding and pain and achieve hemostasis and coagulopathy correction, as well as prophylactic treatment such as before dental procedures and before and after surgery to prevent bleeding episodes and improve quality of life. We offer a variety of factor replacement therapies, including human plasma-derived and recombinant clotting-factor concentrates with and without extended half-life to treat and prevent bleeds in people with hemophilia, von Willebrand disease and other rare bleeding disorders. For plasma-derived therapies, including factor concentrates, we use the most advanced screening and viral inactivation techniques to reduce or eliminate bloodborne infections. We also offer bypassing agents to treat bleeding in patients with hemophilia A and B with inhibitors.

We have expertise in administering nonreplacement therapies, including bispecific antibody therapy such as emicizumab, gene and small interfering ribonucleic acid (RNA) therapies, and recombinant clotting-factor therapies that can be used preventatively. While not a cure for hemophilia, these therapies may offer patients peace of mind, more freedom from hemorrhage without the need for regular treatment with drugs, and longer lifespans. Because some of these therapies do not rely on human blood plasma, patients are also not at risk of contracting bloodborne infections, such as hepatitis and human immunodeficiency virus (HIV).

We offer pharmacologic options, including desmopressin (DDAVP) to help reduce bleeding in patients with mild hemophilia and antifibrinolytics such as aminocaproic acid and tranexamic acid to prevent the breakdown of blood clots in people with hemophilia A and B and von Willebrand disease. We also offer pain management using multimodal treatments such as medications, steroids and physical therapy. Hormone therapy, such as birth control pills, is also used to reduce menstrual bleeding in patients with von Willebrand disease.

If surgery is needed to manage bleeding complications like joint bleeding or other soft-tissue concerns, our multidisciplinary team of orthopedic surgeons and surgical specialists provides the latest advancements in open, minimally invasive and robotic surgery.

Clotting Disorders

We also specialize in the diagnosis and treatment of the full range of thrombotic disorders in adults and children, including those leading to venous thromboembolism and arterial thrombosis.

Our doctors conduct thorough prothrombotic risk-factor assessments, identifying concomitant medical comorbidities such as congenital heart defects, solid-organ transplantation and cancer, along with past and family history of blood clots. They also evaluate other risk factors like pregnancy, hormone therapy, immobility, malignancy, infection, obesity, smoking, central venous catheter use and surgical interventions.

We use advanced hypercoagulability testing for congenital thrombophilia disorders, such as antithrombin III deficiency, factor V Leiden mutation, and protein C and S deficiency, and acquired thrombophilia testing, such as antiphospholipid antibody testing, including lupus anticoagulant and IgG/IgM anticardiolipin and serum D-dimer testing. We also offer the latest venous duplex ultrasonography, as well as ventilation-perfusion scans and computed tomography (CT) pulmonary angiography to detect a pulmonary embolus.

Depending on the cause, we offer the latest pharmacological treatments that target procoagulant factors for venous thromboembolism management and antiplatelet agents, either as monotherapy or dual-antiplatelet therapy, for arterial thrombosis management. We use a wide range of anticoagulant agents, including direct oral anticoagulants, such as dabigatran, apixaban, edoxaban and rivaroxaban, vitamin K antagonists like warfarin, and low-molecular-weight heparin.

Our multidisciplinary team of vascular specialists offers a variety of the latest endovascular treatments, including catheter-directed thrombolysis, percutaneous aspiration thrombectomy, venous balloon dilation and pharmacomechanical catheter-directed thrombolysis, administering “clot-busting” drugs directly into the clot. In certain cases, inferior vena cava (IVC) filters, including retrievable IVC filters, are also offered.

Illustration of two lab technicians holding test tubes standing in front of a wall with multitude of lab samples illustrations.

Clinical Trials for Hematology (Blood Disorders)

Find a clinical trial that is right for you.

Research & Clinical Trials for Bleeding & Clotting Disorders

We are leading collaborative research and actively participating in Centers for Disease Control and Prevention-, Maternal and Child Health Bureau-, American Thrombosis and Hemostasis Network (ATHN)-, and National Institutes of Health-sponsored studies, as well as other investigator-initiated and industry-funded clinical trials. Through our clinical trials, our patients can access emerging technologies and innovative treatments that are otherwise unavailable to the general public. 

Our patients can also access the ATHNdataset, a national database used to support research and improve care. We are also participating in a longitudinal natural history observational cohort study being conducted at ATHN-affiliated sites to determine the safety, effectiveness and practice of therapies used in the treatment of hemophilia, von Willebrand disease, congenital platelet disorders, rare disorders, bleeding not otherwise specified, thrombosis/thrombophilia and non-neoplastic hematologic conditions. 

We also reported the clinical and laboratory coagulation characteristics of pediatric and young-adult patients treated for symptomatic COVID‐19 and were instrumental in developing the American Society of Hematology guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19.

Older couple sitting side by side on an airplane, looking at a smartphone near the window.

Care Navigation & Support Services for Bleeding & Clotting Disorders

If you or your child is newly diagnosed with a bleeding or clotting disorder or currently receiving treatment, our world-renowned team at Montefiore Einstein Hematology (Blood Disorders) is here to provide you with exceptional support, care and resources. Our full-service Center offers a comprehensive range of traditional and holistic care, from screening, prevention and diagnosis to treatment and recovery, including social and support services, genetic counseling and education. Our expansive breadth of resources enables us to deliver highly specialized and coordinated care that considers the whole person, addressing everyone’s complex medical needs and improving quality of life. Our team of compassionate and deeply knowledgeable doctors, nurses, specialists and support staff is dedicated to helping you at every step of your care journey.

Learn More About Bleeding & Clotting-Disorder Prevention, Screening, Diagnosis and Treatment

Find Psychiatry & Behavioral Sciences Locations

Our Hematology (Blood Disorders) Locations

We have more locations than ever to help you with prevention, diagnosis and treatment.